Therapeutic Peptide Treatment for Dyslipidemic and Vascular Disorders

This invention is directed to use of certain peptide analogs comprising multiple amphipathic helical domains that are able to promote cellular lipid efflux and stimulate lipoprotein lipase activity. As a result, administration of invention peptides lead to reduced incidences of hypertriglyceridemia without inducing toxicity. Existing peptides that stimulate efflux of lipids from cells exhibit unacceptably high toxicity. Invention peptides are superior to existing peptides and can also be used to treat or prevent a vast range of vascular diseases, and their dyslipidemic precursors. Exemplary vascular diseases and conditions that could benefit from treatment with the invention peptides include: dyslipidemia, hyperlipidemia, hypercholesterolemia, HDL deficiency, coronary heart disease, atherosclerosis, and thrombic stroke.

Potential Commercial Applications: Competitive Advantages:
  • Treatment of dyslipidemic and vascular disorders
  • Method of identifying therapeutic non-cytotoxic peptides
  • Specific control of lipid efflux and transport
  • Transient hypertriglyceridemia with no reported toxicity

Development Stage:
  • Early-stage
  • Pre-clinical
  • In vitro data available
  • In vivo data available (animal)


Alan Remaley (NHLBI)  ➽ more inventions...

Marcelo Amar (NHLBI)  ➽ more inventions...

Intellectual Property:
U.S. Pat: 8,936,787 issued 2015-01-20
US Application No. 12/937,974
PCT Application No. PCT/US2009/040560

Remaley AT, et al. PMID 12562845
Sviridov DO, et al. PMID 21672528
Osei-Hwedieh DO, et al. PMID 21172387

Collaboration Opportunity:

The National Heart, Lung, and Blood Institute is seeking parties interested in collaborative research to further co-develop novel ApoC-II mimetic peptides for the treatment of hypertriglyceridemia. For collaboration opportunities, please contact Denise Crooks at

Licensing Contact:
Michael Shmilovich, J.D.
Phone: 301-435-5019

OTT Reference No: E-138-2008-0
Updated: Aug 8, 2016